IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Frederic BESEME et al.

Application No.: 09/446,024

Filed:

December 16, 1999

Docket No.:

ENDOGENETIC RETROVIRAL SEQUENCES, ASSOCIATED WITH 5

AUTOIMMUNE DISEASES OR WITH PREGNANCY DISORDERS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

§1.97(e)(2).

Sir:

For:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

				· ·		- 1		
\boxtimes		S. filing	date or the	date of filing	a CPA, OR (b) before the ma	hin three months o ailing date of a firs ion or fee is requir	st
	2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.							
		patent	ation Discioffice in a	losure Statem counterpart fo	oreign applicat	n a communication not more th	ned in this ation from a foreign nan three months 37 CFR §1.97(e)(
-		counte	ent was cit rpart foreig	ted in a comm gn application	unication from or, to my know	a foreign pate wledge after m	nformation Disclosent office in a aking reasonable §1.56(c) more than	

Attached is our check no. _____ in the amount of \$240.00 in payment of the fee under 37 CFR §1.17(p). Please credit or debit Deposit Account No. 15-0461 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

three months prior to the filing of this Information Disclosure Statement. 37 CFR

	3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our Check No in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please credit or debit Deposit Account No. 15-0461 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.									
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).								
		b. I hereby certify that no item of information in this Information Disc Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more to three months prior to the filing of this Information Disclosure Statement. 3 §1.97(e)(2).								
		Respectfully submitted, Milliam P. Berridge Registration No. 30,024	RECEIVED NAR 29 2000 TC 1600 MAIL RO							

Thomas J. Pardini Registration No. 30,411

WPB:TJP/kmc

OLIFF & BERRIDGE, PLC P.O. Box 19928 Alexandria, Virginia 22320 Telephone: (703) 836-6400 DEPOSIT ACCOUNT USE
AUTHORIZATION
Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461